Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AbbVie patents lysophospholipid S1P5 receptor agonists

Feb. 8, 2019

Solid seeks to escalate dose in IGNITE DMD trial of SGT-001 following preliminary findings

Feb. 7, 2019

Axsome reaches SPA agreement with FDA on phase III trial for AXS-07 for acute migraine

Feb. 7, 2019

Sichuan Haisco Pharmaceutical describes kappa-opioid receptor agonists

Feb. 7, 2019

MEK/ERK2 pathway regulates Shank3 stability: a novel target for SHANK3-related disorders

Feb. 7, 2019

Membrane rips kill axons in MS

Feb. 7, 2019

Capricor resumes CAP-1002 dosing of enrolled HOPE-2 DMD patients

Feb. 6, 2019

Researchers mimic human Batten disease in a porcine model

Feb. 6, 2019

Boehringer and Hydra Biosciences patent TRPC5 antagonists

Feb. 6, 2019

FDA agrees Cytogel may proceed with phase Ia/IIa study of CYT-1010

Feb. 6, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...